Aurinia Pharmaceuticals Inc(AUPH)stock report

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Q3 2019(9/30/19): Cash 131M. Loss 15.9M

EPS and Sales:

Date EPS % last year % last quarter
2018.9.30 -0.59 35.16% -37.29%
2018.12.31 -0.76 17.39% -28.81%
 2019.3.31 -0.14 22.22% 81.58%
2019.6.30 -0.31 16.22% 121.43%


Date Sales % last year % last quarter
2018.9.30 0.43M 11.86% 86.05%
2018.12.31 0.46M 10.77% 6.98%
 2019.3.31 0.03M 0.00% -93.48%
2019.6.30 0.05M 0.00% 66.67%


Insider Transactions:

Institution Ownership:

Total institutions: 79,no change
Shares hold: 30228.3k shares. no change
shares% hold: 32.92%,no change

Analyst Ratings:

2019-12-09: Aurinia Prices US$166.7 Million Public Offering of Common Shares

2019-12-04: Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

2019-11-14: Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

2018-03-26: Aurinia Pharma inks $40M stock sales deal with Jefferies

Leave a Reply